---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000078"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:30:09.906757+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue

## Summary
- VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.
- Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.
- Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.
- VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.
- First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK).

## SEC filing metadata
- accession: 0001711279-25-000078
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/0001711279-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/krys-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000078
- JSON: https://secwatch.observer/filing/0001711279-25-000078.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.